1 withdrawn. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Withdrawn 1 |
Follow Chafic Karam: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome Efgartigimod Alfa-Fcab, Intravenous Immunoglobulin (IVIg) - Guillain-Barre Syndrome | Phase 2 | Withdrawn | Chafic Karam | 2024-09-10 | 2026-03-12 |
Immunoglobulins, Intravenous (1) · efgartigimod alfa (1)
United States (1)
Colin Quinn, MD (1)